(Q40278672)

English

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru

scientific article published on 31 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru (English)

1 reference

Europe PubMed Central

19 September 2017

0 references

yellow fever virus

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Claudio F Lanata

1

1 reference

Europe PubMed Central

19 September 2017

Teresa Andrade

2

1 reference

Europe PubMed Central

19 September 2017

Ana I Gil

3

1 reference

Europe PubMed Central

19 September 2017

Cynthia Terrones

4

1 reference

Europe PubMed Central

19 September 2017

Omar Valladolid

5

1 reference

Europe PubMed Central

19 September 2017

Betzana Zambrano

6

1 reference

Europe PubMed Central

19 September 2017

Melanie Saville

7

1 reference

Europe PubMed Central

19 September 2017

Denis Crevat

8

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

31 July 2012

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

30

1 reference

Europe PubMed Central

19 September 2017

41

1 reference

Europe PubMed Central

19 September 2017

5935-5941

1 reference

Europe PubMed Central

19 September 2017

The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Dengue: a continuing global threat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Review of dengue virus and the development of a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Next generation dengue vaccines: a review of candidates in preclinical development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Dengue virus serotype 4, northeastern Peru, 2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.043

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.07.043

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40278672&oldid=1892415167"